Botulinum Toxin Type A (BoNT-A) Use for Post-Stroke Spasticity: A Multicenter Study Using Natural Language Processing and Machine Learning.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
02 Aug 2024
Historique:
received: 30 05 2024
revised: 30 07 2024
accepted: 30 07 2024
medline: 28 8 2024
pubmed: 28 8 2024
entrez: 28 8 2024
Statut: epublish

Résumé

We conducted a multicenter and retrospective study to describe the use of botulinum toxin type A (BoNT-A) to treat post-stroke spasticity (PSS). Data were extracted from free-text in electronic health records (EHRs) in five Spanish hospitals. We included adults diagnosed with PSS between January 2015 and December 2019, stratified into BoNT-A-treated and untreated groups. We used EHRead

Identifiants

pubmed: 39195750
pii: toxins16080340
doi: 10.3390/toxins16080340
pii:
doi:

Substances chimiques

Botulinum Toxins, Type A EC 3.4.24.69
Neuromuscular Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ipsen
ID : 0000000

Auteurs

María Jesús Antón (MJ)

Department of Physical Medicine and Rehabilitation, Rio Hortega University Hospital, 47007 Valladolid, Spain.

Montserrat Molina (M)

Department of Physical Medicine and Rehabilitation, University Hospital of Fuenlabrada, 28942 Madrid, Spain.

José Gabriel Pérez (JG)

Department of Physical Medicine and Rehabilitation, Son Espases University Hospital, 07210 Palma de Mallorca, Spain.

Santiago Pina (S)

Department of Physical Medicine and Rehabilitation, General University Hospital, 12004 Castellón, Spain.

Noemí Tapiador (N)

Department of Physical Medicine and Rehabilitation, University Hospital Puerta de Hierro-Majadahonda, 28222 Madrid, Spain.

Beatriz De La Calle (B)

Department of Physical Medicine and Rehabilitation, Rio Hortega University Hospital, 47007 Valladolid, Spain.

Mónica Martínez (M)

Department of Physical Medicine and Rehabilitation, University Hospital of Fuenlabrada, 28942 Madrid, Spain.

Paula Ortega (P)

Department of Physical Medicine and Rehabilitation, University Hospital Puerta de Hierro-Majadahonda, 28222 Madrid, Spain.

María Belén Ruspaggiari (MB)

Department of Physical Medicine and Rehabilitation, Son Espases University Hospital, 07210 Palma de Mallorca, Spain.

Consuelo Tudela (C)

Department of Physical Medicine and Rehabilitation, General University Hospital, 12004 Castellón, Spain.

Marta Conejo (M)

Department of Physical Medicine and Rehabilitation, University Hospital of Fuenlabrada, 28942 Madrid, Spain.

Pedro Leno (P)

Department of Physical Medicine and Rehabilitation, Son Espases University Hospital, 07210 Palma de Mallorca, Spain.

Marta López (M)

Department of Physical Medicine and Rehabilitation, General University Hospital, 12004 Castellón, Spain.

Carmen Marhuenda (C)

Department of Physical Medicine and Rehabilitation, University Hospital Puerta de Hierro-Majadahonda, 28222 Madrid, Spain.

Carlos Arias-Cabrales (C)

Savana Research S.L, 28004 Madrid, Spain.

Pascal Maisonobe (P)

Department of Biometry, Ipsen Pharma, 92100 Boulogne-Billancourt, France.

Alberto Herrera (A)

Medical Affairs, Ipsen Pharma, 28050 Madrid, Spain.

Ernesto Candau (E)

Department of Physical Medicine and Rehabilitation, Rio Hortega University Hospital, 47007 Valladolid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH